Peer reviewed research published in Pediatric Neurology Briefs showed that, in an analysis of cannabidiol products purchased on the internet, a majority were mislabeled. Almost half contained more CBD than labeled while nearly a quarter contained less...
The researchers from the University of Pennsylvania, Veterans Affairs San Diego, RTI international, Americans for Safe Access, Palo Alto University and Johns Hopkins University tested 84 cannabidiol products purchased on the internet. They found that 26% contained less CBD than labeled and 43% contained more. They also found that THC was present in 21% of the products tested; potentially at concentrations high enough to cause intoxication in children.
The abstract points out that their results were alarming and demonstrate that many of the products currently on the market are not being properly regulated despite FDA attempts at addressing the issue. In the study commentary the researchers noted that, "Overall, the results of this study are an important contribution to the growing evidence that online CBD products have a high rate of mislabeling. A need exists for consistency and regulation of these products..."
This study shows that, presently, there is a lack of standardization and a high rate of mislabeling when it comes to CBD products. For CBD to be seen as an effective and safe medicinal treatment option such issues must be resolved. The potential for adverse reactions due to questionable products with unknown strengths is serious. Until products can be expected to contain what their labels state, the usage of CBD in medicine will face understandable scrutiny.